Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

INO hizo una agrupación de acciones (split inverso) de 1:12 el 25 de enero de 2024: cada 12 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 30 sept

  PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

  Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.

  

• GlobeNewswire Inc. 30 sept

  Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

  The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

  

• Zacks Investment Research 14 sept

  Bet on 4 Top-Ranked Stocks With Rising P/E

  The article explores how stocks with rising P/E ratios paired with accelerating earnings growth can deliver strong returns. Using specific screening criteria focused on earnings momentum and price performance, the analysis identifies four stocks: H World Group Limited (HTHT), Inovio Pharmaceuticals (INO), Nouveau Monde Graphite (NMG), and Cogent Communications (CCOI) as potential outperformers with consistent price gains and strong earnings surprises.

  

• Zacks Investment Research 3 sept

  Bet on 5 Top-Ranked Stocks With Rising P/E

  The article explores how rising P/E ratios, combined with accelerating earnings growth and sustained price momentum, can indicate strong investment opportunities. Five stocks meeting these criteria are highlighted: CuriosityStream (CURI), Inovio Pharmaceuticals (INO), GDS Holdings (GDS), Nouveau Monde Graphite (NMG), and Cogent Communications (CCOI). These companies demonstrate consistent price gains relative to the S&P 500 and positive earnings trends.

  

• GlobeNewswire Inc. 21 jul

  Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

  The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.